Budget impact analysis of biosimilar natalizumab in the US.
Edward LiAdrian GohSoni GuptaMarion SchaufAnna ChenDaniel M Hartung
Published in: The American journal of managed care (2024)
Adoption of biosimilar NTZ can yield considerable cost savings to US health plans that could result in increased treatment access for patients with RRMS.